Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer

William P. McGuire; Richard T. Penson; Martin Gore; Antonio Casado Herraez; Patrick Peterson; Ashwin Shahir; Robert Ilaria

doi:10.1186/s12885-018-5198-4

Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer

BMC Cancer ◽

10.1186/s12885-018-5198-4 ◽

2018 ◽

Vol 18 (1) ◽

Cited By ~ 10

Author(s):

William P. McGuire ◽

Richard T. Penson ◽

Martin Gore ◽

Antonio Casado Herraez ◽

Patrick Peterson ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Study ◽

Advanced Ovarian Cancer ◽

Platinum Resistant ◽

Randomized Phase Ii ◽

Platinum Refractory

Download Full-text

Faculty Opinions recommendation of PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718144304.793486590 ◽

2013 ◽

Author(s):

Roberto Angioli

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Pegylated Liposomal Doxorubicin ◽

Platinum Resistant ◽

Randomized Phase Ii

Download Full-text

BAROCCO: A randomized phase II study of weekly paclitaxel vs cediranib-olaparib with continuous schedule vs cediranib-olaparib with intermittent schedule in advanced platinum resistant ovarian cancer

Annals of Oncology ◽

10.1093/annonc/mdy285.209 ◽

2018 ◽

Vol 29 ◽

pp. viii357

Author(s):

N. Colombo ◽

O. Nicoletto ◽

P. Benedetti Panici ◽

G. Tognon ◽

A.A. Lissoni ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Weekly Paclitaxel ◽

Intermittent Schedule ◽

Platinum Resistant ◽

Randomized Phase Ii

Download Full-text

Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2005.08.020 ◽

2006 ◽

Vol 100 (2) ◽

pp. 318-323 ◽

Cited By ~ 27

Author(s):

M.O. Nicoletto ◽

C. Falci ◽

D. Pianalto ◽

G. Artioli ◽

P. Azzoni ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Study ◽

Advanced Ovarian Cancer ◽

Pegylated Liposomal Doxorubicin

Download Full-text

Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.5547 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 5547-5547 ◽

Cited By ~ 5

Author(s):

Ursula A. Matulonis ◽

Amit M. Oza ◽

Angeles Alvarez Secord ◽

Lynda D. Roman ◽

Sarah Patricia Blagden ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Hypomethylating Agent ◽

Platinum Resistant ◽

Randomized Phase Ii

Download Full-text

A Phase II Study of Patupilone (EPO906) in Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer

Clinical Ovarian and Other Gynecologic Cancer ◽

10.1016/j.cogc.2012.06.001 ◽

2012 ◽

Vol 5 (2) ◽

pp. 53-59 ◽

Cited By ~ 2

Author(s):

Willem M. Smit ◽

Jozef Šufliarsky ◽

Theresa L. Werner ◽

Don S. Dizon ◽

Maria Wagnerová ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Platinum Resistant ◽

Platinum Refractory

Download Full-text

38 Influence of amifostine on neuroprotection in 1st-line treatment of advanced ovarian cancer with carboplatin/taxane-based chemotherapy - a double-blind, placebo-controlled, randomized phase II-study from the AGO Ovarian Cancer Study Group

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(03)90072-3 ◽

2003 ◽

Vol 1 (5) ◽

pp. S15-S16

Author(s):

P. Wimberger ◽

R. Kimmig ◽

F. Hilpert ◽

A. Stähle ◽

A. Burges ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Ovarian Cancer ◽

Study Group ◽

Line Treatment ◽

Double Blind ◽

Double Blind Placebo ◽

Cancer Study Group ◽

Randomized Phase Ii

Download Full-text

Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer

International Journal of Gynecological Cancer ◽

10.1111/j.1525-1438.2006.00298.x ◽

2006 ◽

Vol 16 (1) ◽

pp. 65-70 ◽

Cited By ~ 22

Author(s):

M. VERHAAR-LANGEREIS ◽

A. KARAKUS ◽

M. van EIJKEREN ◽

E. VOEST ◽

E. WITTEVEEN

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Study ◽

Pegylated Liposomal Doxorubicin ◽

Platinum Resistant

Download Full-text

BAROCCO: A randomized phase II study of weekly paclitaxel vs cediranib-olaparib combination given with continuous or intermittent schedule in patients with recurrent platinum resistant ovarian cancer (PROC)

Annals of Oncology ◽

10.1093/annonc/mdz394.055 ◽

2019 ◽

Vol 30 ◽

pp. v896 ◽

Cited By ~ 3

Author(s):

N. Colombo ◽

M.O. Nicoletto ◽

P. Benedetti Panici ◽

G. Tognon ◽

A. Bologna ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Weekly Paclitaxel ◽

Intermittent Schedule ◽

Platinum Resistant ◽

Randomized Phase Ii

Download Full-text

Faculty Opinions recommendation of Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.737186538.793572794 ◽

2020 ◽

Author(s):

Diana English ◽

Andrea Buras

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Ovarian Cancer ◽

Front Line ◽

Randomized Phase Ii

Download Full-text

PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.5045 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 5045-5045 ◽

Cited By ~ 15

Author(s):

R. W. Naumann ◽

R. L. Coleman ◽

R. A. Burger ◽

T. J. Herzog ◽

R. Morris ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Pegylated Liposomal Doxorubicin ◽

Platinum Resistant ◽

Randomized Phase Ii

Download Full-text